LIAS

Across TCGA pan-cancer cohorts, LIAS Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated LIAS data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LIAS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LIAS expression acts as an unfavorable survival marker, although some lineages such as OV and SKCM show a favorable association.

LUAD, OV, and LUSC are the cancer types where LIAS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.068	0.788	<.001	21	view →
OV	OS	Median	III,IV	0.791	0.309	.041	6	view →
LUSC	DFS	Median	II,III,IV	0.172	0.614	.002	6	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
COAD	DFS	Median	All	0.152	0.564	.033	4	view →
SKCM	DFS	Median	III,IV	1.000	0.467	.027	4	view →
BRCA	DFS	Median	All	0.225	0.528	.043	2	view →
UCEC	OS	Median	All	0.973	0.865	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

LIAS–LUAD (OS)

Open the LUAD breakdown →